Filer Snapshot

Enavate Sciences GP, LLC

CIK 0001953107. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

12

Latest filing

15 May 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Largest parsed holding

SION

$99.34M reported value

Open holding

13D/G large stake

CAMP

09 Mar 2026 · 4.8% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Form 13F

13F-HR filed on 15 May 2026 for CIK 0001953107.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$351.51M

Quarterly institutional holdings reported on Form 13F; not total AUM.

Forms 3/4/5 positions$63.94M

Reporting-owner positions with enough filing detail to estimate value.

Latest reported 13F value

13F
$351.51M

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Forms 3/4/5 position value

3/4/5
$63.94M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest 13F holdings

13F
SION IMNM ZBIO CMPX BBOT
+2 moreUPB CAMP

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

ZBIO

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

SION IMNM ZBIO CMPX BBOT UPB CAMP

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

ZBIO IMNM SION CAMP
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
106 W 56 Th St., Floor 8, New York, NY, 10019
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Enavate Sciences GP, LLC

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $351.51M across 7 reported holdings for Q1 2026.
  • Largest parsed 13F holding: SION at $99.34M.
  • 4 recent 13D/G stake rows found; top row is CAMP at 4.8% ownership.
  • Forms 3/4/5 show insider context for ZBIO worth $63.94M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 7 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 4 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 2 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2026 - 15 May 2026

Top 5 concentration

91%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$319.71M

Compared with $351.51M total 13F value.

Top 5 net change

-$25.26M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest trim: IMNM

SION IMNM ZBIO CMPX BBOT Other holdings

SION

28.3%

Sionna Therapeutics Inc

$99.34M

IMNM

22.5%

Immunome Inc

$79.03M

ZBIO

21.8%

Zenas Biopharma Inc

$76.62M

CMPX

11.7%

Compass Therapeutics Inc

$41.2M

BBOT

6.7%

Bridgebio Oncology Therapeut

$23.51M

13D/G large-stake context

CAMP

09 Mar 2026 · Common Stock, $0.0001 par value per share

4.8%
Issuer page 13D/G history

IMNM

18 Dec 2025 · Common Stock, par value $0.0001 per share

4.3%
Issuer page 13D/G history

ZBIO

09 Oct 2025 · Common Stock, par value $0.0001 per share

7.3%
Issuer page 13D/G history

SION

10 Feb 2025 · Common Stock, $0.001 par value per share

5.6%
Issuer page 13D/G history

Forms 3/4/5 insider context

ZBIO

16 Sep 2024 · 10% owner

$63.94M
Issuer page Owner page

CAMP

15 Oct 2024 · 10% owner

Issuer page Owner page

Latest update

What changed recently for Enavate Sciences GP, LLC

New filing available

Latest 13F period: Q1 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

15 May 2026

Page type

Filer profile

Latest period

Q1 2026

Institutional portfolio context was refreshed from a 13F filing filed on 15 May 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

Enavate Sciences GP, LLC has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q1 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001953107 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
12
First seen
14 Feb 2025
Latest filing
15 May 2026
Entity
Company

Observed form types

13F-HR SCHEDULE 13D SCHEDULE 13D/A

CIK-linked evidence first

Enavate Sciences GP, LLC SEC filings Enavate Sciences GP, LLC 13F portfolio Enavate Sciences GP, LLC 13D/G history Enavate Sciences GP, LLC owner filings Open SEC filing index

Latest Filings

Showing the latest 12 of 12 SEC filings for Enavate Sciences GP, LLC.

13F-HR

13F-HR filing

Filing date
15 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
11 Mar 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
17 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
23 Dec 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
22 Dec 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Nov 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
14 Oct 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
15 Sep 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
15 May 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D

SCHEDULE 13D filing

Filing date
18 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Feb 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .